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Disrupted Murine Gut–to–Human Liver Signaling Alters Bile Acid
Homeostasis in Humanized Mouse Liver Models s
Edwin C. Y. Chow, Holly P. Quach, Yueping Zhang, Jason Z. Y. Wang, David C. Evans,
Albert P. Li, Jose Silva, Rommel G. Tirona, Yurong Lai, and K. Sandy Pang
Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
(E.C.Y.C., H.P.Q., J.Z.Y.W., K.S.P.); Bristol Myers Squibb, Pharmaceutical Candidate Optimization Department, Princeton, New
Jersey (Y.Z., Y.L.); Pharmacokinetics, Dynamics, and Metabolism, Janssen Research and Development, LLC, Spring House,
Pennsylvania (D.C.E., J.S.); In Vitro ADMET Laboratories, Columbia, Maryland (A.P.L.); Department of Physiology and
Pharmacology and Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario,
Canada (R.G.T.)

ABSTRACT
The humanized liver mouse model is being exploited increasingly for human drug metabolism studies. However, its model stability, intercommunication between human hepatocytes and mouse
nonparenchymal cells in liver and murine intestine, and changes
in extrahepatic transporter and enzyme expressions have not
been investigated. We examined these issues in FRGN [fumarylacetoacetate hydrolase (Fah2/2), recombination activating
gene 2 (Rag22/2), and interleukin 2 receptor subunit gamma
(IL-2rg 2/2) triple knockout] on nonobese diabetic (NOD) background] and chimeric mice: mFRGN and hFRGN (repopulated
with mouse or human hepatocytes, respectively). hFRGN mice
showed markedly higher levels of liver cholesterol, biliary
bilirubin, and bile acids (liver, bile, and plasma; mainly human
forms, but also murine bile acids) but lower transforming growth
factor beta receptor 2 (TGFBR2) mRNA expression levels (10%)
in human hepatocytes and other proliferative markers in mouse
nonparenchymal cells (Tgf-b1) and cholangiocytes [plasma
membrane–bound, G protein-coupled receptor for bile acids
(Tgr5)], suggestive of irregular regeneration processes in hFRGN

Introduction
Humanized (h-chimeric) liver mouse models are preclinical
tools that are used for the prediction of human drug metabolism (Sanoh and Ohta, 2014). Unlike the transgenic mouse
models, h-chimeric liver mouse models that are repopulated
with human hepatocytes consist of the full complementary array of human liver genes. The triple genetic knockout FRGN
mouse model [fumarylacetoacetate hydroxylase (Fah2/2),
recombination-activating gene 2 (Rag22/2 ), and interlukin 2
receptor subunit gamma (Il2rg2/2) triple knockout] on nonobese diabetic strain (NOD) background] is one of these
models in which absence of the Fah gene results in liver
accumulation of the toxic metabolite, fumarylacetoacetate,
which induces hepatic injury and allows for repopulation of
foreign hepatocytes (Azuma et al., 2007). Toxicity is alleviated
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livers. Changes in gene expression in murine intestine, kidney,
and brain of hFRGN mice, in particular, induction of intestinal
farnesoid X receptor (Fxr) genes: fibroblast growth factor 15
(Fgf15), mouse ileal bile acid binding protein (Ibabp), small
heterodimer partner (Shp), and the organic solute transporter
alpha (Osta), were observed. Proteomics revealed persistence of
remnant murine proteins (cyotchrome P450 7a-hydroxylase
(Cyp7a1) and other enzymes and transporters) in hFRGN livers
and suggest the likelihood of mouse activity. When compared with
normal human liver tissue, hFRGN livers showed lower SHP
mRNA and higher CYP7A1 (300%) protein expression, consequences of tb- and ta-muricholic acid–mediated inhibition of the
FXR-SHP cascade and miscommunication between intestinal
Fgf15 and human liver fibroblast growth factor receptor 4 (FGFR4),
as confirmed by the unchanged hepatic pERK/total ERK ratio.
Dysregulation of hepatocyte proliferation and bile acid homeostasis in hFRGN livers led to hepatotoxicity, gallbladder distension,
liver deformity, and other extrahepatic changes, making questionable the use of the preparation for drug metabolism studies.

when these mice are given daily supplements of 2-(2-nitro-4trifluoro-methylbenzoyl)-1,3-cyclohexanedione (NTBC), which
blocks fumarylacetoacetate production and allows for a controllable environment in which a series of hepatocyte implantations for successful engraftment can be achieved.
The h-chimeric liver mouse models are being used increasingly for human drug metabolism studies (Katoh et al., 2004;
Tateno et al., 2004; Katoh et al., 2005a, b, 2007; Ohtsuki et al.,
2014) and have provided preliminary insights on human
metabolite formation in vivo (Liu et al., 2011; Sanoh et al.,
2012; Bateman et al., 2014; Kitamura and Sugihara, 2014).
These mice respond to selective induction of ligands for humanspecific nuclear receptors (Katoh et al., 2005a; Emoto et al.,
2008; Sanoh and Ohta, 2014). In addition, h-chimeric liver
mouse models have been used to study preclinical drugdrug interactions (Jaiswal et al., 2014) and drug-induced
liver injury stemming from troglitazone (Barnes et al.,
2014; Samuelsson et al., 2014), bosentan (Xu et al., 2015),
and fialuridine (Xu et al., 2014), and have provided an
essential in vivo safety testing tool for potential human toxic
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bile acid species by liquid chromatography coupled with
tandem mass spectrometry (LC-MS/MS) and employed proteomics to quantify changes in mouse and human CYP7A1
and other proteins. We included mFRGN mice (FRGN liver
with foreign mouse hepatocyte repopulation) in this study as
another control to ensure that observations were independent
of the diet/housing and surgical manipulation (Chow et al.,
2016). Because the status of each organ/tissue could potentially impact the functionality of others (Naud et al., 2007,
2008), we appraised key biologic and physiologic parameters,
and human and mouse gene expression in liver, including
proliferative genes in nonparenchymal cells and in extrahepatic tissues to fully understand the interorgan communication between human and mouse organs in hFRGN mice.

Methods
Materials. Cholic acid (CA), chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), lithocholic acid (LCA), ursodeoxycholic acid
(UDCA), taurocholic acid (tCA) sodium salt hydrate, taurochenodeoxycholic acid (tCDCA) sodium salt, taurodeoxycholic acid (tDCA)
sodium salt, and taurolithocholic acid (tLCA) sodium salt were
obtained from Sigma Aldrich Canada (Oakville, ON). Muricholic acid
(MCA), a-, b-, and v-muricholic acids (a-, b-, and v-MCA), tauro-a-,
tauro-b- and tauro-v-muricholic acid (ta-, tb-, and tv-MCA) sodium
salts, and tauroursodeoxycholic acid (tUDCA) sodium salt were
obtained from Steraloids (Newport, RI). Glycocholic acid (gCA),
glycochenodeoxycholic acid (gCDCA), glycodeoxycholic acid (gDCA),
glycolithocholic acid (gLCA), and glycoursodeoxycholic acid (gUDCA)
were kind gifts from Dr. Alan F. Hofmann (University of California,
San Diego). Cholic-2,2,4,4-d4 acid (CA-d4), chenodeoxycholic-2,2,4,4-d4
acid (CDCA-d4), deoxycholic-2,2,4,4-d4 acid (DCA-d4), and lithocholic2,2,4,4-d4 acid (LCA-d4) were purchased from C/D/N Isotopes (PointeClaire, QC).
Mice and Housing Conditions. Male FRGN, mFRGN [FRGN
livers repopulated with pooled mouse hepatocytes of the Rosa (129S7)
mouse strain], and hFRGN [FRGN livers with human hepatocyte
repopulation] mice (4–6 months old from three different human
donors of ages 5, 7, and 17, Table 1) were supplied by Yecuris
Corporation (Tualatin, OR). All hFRGN livers were .80% human
repopulated, as stated by Yecuris. The housing and diet conditions of
FRGN, mFRGN, and hFRGN mice have been previously described in
detail by Chow et al. (2016). All animal studies were performed in
accordance to approved animal protocols at the University of Toronto.

ABBREVIATIONS: a-, b-, and v-MCA, a-, b-, and v-muricholic acids; ACN, acetonitrile; ALT, alanine aminotransferase; Baat/BAAT, murine/
human bile acid CoA/amino acid N-acyltransferase; Bcrp/BCRP, murine/human breast cancer resistance protein; Bsep/BSEP, murine/human bile
salt export pump; CA, cholic acid; Car/CAR, murine/human constitutive androstane receptor; CDCA, chenodeoxycholic acid; Cyp7a1/CYP7A1,
murine/human cytochrome P450 7a-hydroxylase; DCA, deoxycholic acid; ddH2O, double-distilled water; ELISA, enzyme-linked immunosorbent
assay; Fgf15/FGF19, rodent or human fibroblast growth factor 15/19; Fgfr4/FGFR4, murine/human fibroblast growth factor receptor 4; FRGN, triple
knockout of Fah, Rag2, and Il2rg genes on the nonobese diabetic strain background; Fxr/FXR, murine/human farnesoid X receptor; gCA,
glycocholic acid; gCDCA, glycochenodeoxycholic acid; gDCA, glycodeoxycholic acid; gLCA, glycolithocholic acid; gUDCA, glycoursodeoxycholic
acid; GAPDH, human glyceraldehyde-3-phosphate dehydrogenase; Gsta/GSTA, murine/human glutathione S-transferase; hFRGN or h-chimeric,
humanized liver mouse or FRGN mouse with human-hepatocyte repopulated liver; Hnf-4a/HNF-4a, murine/human hepatocyte nuclear factor
4 alpha; LC-MS/MS, liquid chromatography–tandem mass spectrometry; LCA, lithocholic acid; Lrh-1/LRH-1, murine/human liver receptor homolog
1; Lxra/LXR, murine/human liver X receptor alpha; MCA, muricholic acid; Mdr1a/MDR1, murine/human multidrug resistance protein 1; MeOH,
methanol; mFRGN, FRGN mouse with foreign mouse-hepatocyte [Rosa (129S7) strain] repopulated liver; Mrp/MRP, murine/human multidrug
resistance–associated protein; MRM, multiple reaction monitoring; NH4OH, ammonium hydroxide; NTBC, nitisinone or 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione; Ntcp/NTCP, murine/human sodium-dependent taurocholate–cotransporting polypeptide; Oat, mouse
organic anion transporter; Oatp/OATP, murine/human organic anion–transporting polypeptide; Ost/OST, murine/human organic solute transporter
(a or b); P-gp, P-glycoprotein; Pxr/PXR/SXR, murine/human pregnane X receptor, also known as steroid X receptor; Shp/SHP, murine/human small
heterodimer partner; ta-, tb-, and tv-MCA, tauro-a-, tauro-b-, tauro-v-muricholic acid; tCA, taurocholic acid; tCDCA, taurochenodeoxycholic acid;
tDCA, taurodeoxycholic acid; TGF-b1/TGF-b, transforming growth factor beta; TGFBR2, transforming growth factor beta receptor 2; Tgr5, plasma
membrane–bound, G protein-coupled receptor for bile acids; tLCA, taurolithocholic acid; tUDCA, tauroursodeoxycholic acid; UDCA,
ursodeoxycholic acid; Ugt/UGT, murine/human UDP-glucuronosyltransferases
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metabolites (Strom et al., 2010; Cohen, 2014; Kitamura and
Sugihara, 2014; Xu et al., 2015).
A sound comparison of the pharmacokinetic and metabolic
data with h-chimeric liver mouse models is dependent on the
premise that the model is stable, with little or no change in
transporters and enzymes in extrahepatic tissues that are also
under regulation by nuclear receptors (Makishima, 2005). The
farnesoid X receptor (FXR), liver X receptor (LXR), pregnane/
steroid X receptor (PXR/SXR), and constitutive androstane
receptor (CAR) are major nuclear receptors that are responsible for the regulation of transporters and enzymes in the
body. Although these nuclear receptors in human and other
species share common targets, species difference in nuclear
receptor activation exists, and this will pose as a major concern
in ligand-specific nuclear receptor activation (Chiang et al.,
2001; Handschin and Meyer, 2003; Katoh et al., 2005a; Sayin
et al., 2013) in the h-chimeric liver model.
We recently observed remarkable physiologic and metabolic zonation differences between hFRGN and FRGN mouse
livers. Notably, hFRGN livers contain remnant mouse transporters and enzymes that are present at similar or even higher
levels than those in FRGN livers (Chow et al., 2016). One
possible explanation is that changes in intrinsic factors such
as hormone and bile acid production, as regulated by intestinal and hepatic nuclear receptors, will lead to changes in
liver transporter and enzyme levels. At high bile acid concentrations, human cytochrome P450 7a-hydroxylase (CYP7A1),
the rate-limiting enzyme for bile acid synthesis, is negatively
regulated by the FXR–small heterodimer partner (SHP)
cascade (Chiang, 2003, 2009) and by the fibroblast growth
factor 15/19 (mouse Fgf15, human ortholog FGF19), a hormone that is secreted by the ileum and binds to liver fibroblast growth factor receptor 4 (FGFR4) to activate the c-Fos
pathway for repressing CYP7A1 in a negative feedback
mechanism (Inagaki et al., 2005; Lin et al., 2007). In h-chimeric
livers, CYP7A1 and human bile acid levels were observed to
be dramatically elevated, but the condition was corrected
upon administration of exogenous FGF19 or transfection of
FGF19 gene in h-chimeric mice (Ellis et al., 2013; Naugler
et al., 2015).
To fully understand bile acid dysregulation in these
h-chimeric mice, we examined individual mouse and human
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TABLE 1
hFRGN human donor and human liver tissue information
All hFRGN livers were .80% human repopulated, as indicated by Yecuris. Human liver tissues were from In Vitro ADMET, Columbia, MD
Mouse ID

Human Donors ID

Donor Information

Human Albumin

Experiments

mg/ml

1
2
3
4
5
6

HHF07007
HHF07007
HHF07007
HHF07007
HHF07007
HHM05010
HHM05010
HHM05010
HHF17006
HHF17006
HHF17007
HHF17007
HHF17006
HHF17006
HHF17006
HHF17006
H1016
H1028
H1041
H1047
H1057
H1072

Female, Caucasian, 7 years old
Female, Caucasian, 7 years old
Female, Caucasian, 7 years old
Female, Caucasian, 7 years old
Female, Caucasian, 7 years old
Male, Caucasian, 5 years old
Male, Caucasian, 5 years old
Male, Caucasian, 5 years old
Female, Caucasian, 17 years old
Female, Caucasian, 17 years old
Female, Caucasian, 7 years old
Female, Caucasian, 7 years old
Female, Caucasian, 17 years old
Female, Caucasian, 17 years old
Female, Caucasian, 17 years old
Female, Caucasian, 17 years old
Female, Hispanic, 64 years old
Male, Hispanic, 43 years old
Male, Caucasian, 53 Years old
Male, Hispanic, 44 years old
Female, Caucasian, 33 years old
Female, Caucasian, 40 years old

7.2
4.9
4.6
5.3
15.5
4.8
4.0
4.0
6.3
7.1
5.7
4.4
5.2
3.9
3.5
3.5
NA
NA
NA
NA
NA
NA

Liver mRNA and protein
Liver mRNA and protein
Liver mRNA and protein
mRNA and protein; bile acid LC-MS/MS
mRNA and protein; bile acid LC-MS/MS
Liver mRNA and protein
mRNA and protein; bile acid LC-MS/MS
Histology
mRNA and protein; bile acid LC-MS/MS
mRNA and protein; bile acid LC-MS/MS
mRNA and protein; bile acid LC-MS/MS
mRNA and protein; bile acid LC-MS/MS
Bile acid pool size LC-MS/MS
Bile acid pool size LC-MS/MS
Bile acid pool size LC-MS/MS
Bile acid pool size LC-MS/MS
Liver mRNA
Liver mRNA
Liver mRNA
Liver mRNA
Liver mRNA
Liver mRNA

NA, not available.

Biologic Assays. Plasma alanine aminotransaminase (ALT) from
fresh plasma samples were immediately quantified by the ALT kit
(Bioquant, Nashville, TN), and plasma and liver cholesterol and liver
triglyceride levels were measured using total cholesterol (Wako
Diagnostics, Richmond, VA, and Thermo Scientific, Rockford, IL,
respectively) and triglyceride (Thermo Scientific) kits, as previously
described by Chow et al. (2014). Total and conjugated bilirubin in
bile were assayed by the bilirubin assay kit (SigmaAldrich Canada)
after a 15-fold dilution with saline.
Oil Red O Staining. After flushing of the mouse liver with ice-cold
saline, livers were fixed with 10% formalin overnight for hematoxylin
and eosin staining, followed by Oil Red O staining, as performed by the
Toronto Centre for Phenogenomics (Toronto, ON).
Bile Acid Quantification from Bile, Plasma, Liver, and Pool
Size Using LC-MS/MS. The bile ducts of FRGN, mFRGN, and
hFRGN mice were cannulated under anesthesia after gallbladder
ligation with PE10 tubing for continuous bile collection in vivo for
10–20 minutes. Blood was then collected by cardiac puncture with a
heparinized needle/syringe, and the sample was centrifuged to obtain
plasma. Ice-cold saline was pushed through the vena cava to flush
blood out of tissues. Enterocytes from intestine [duodenal, proximal
jejunal, and ileal segments, with enterocytes removed by a scraper as
described (Chow et al., 2014)], kidney, liver, and brain were collected,
cut into pieces, snap-frozen in liquid nitrogen, and stored at –80°C for
future analyses.
The detailed description of sample preparation for bile acids in
plasma, bile, and liver tissue, and the bile acid pool size study was as
follows. For bile acid sample preparation, the aliquot was first diluted
100-fold with double-distilled (dd)H2O, followed by addition of 20 ml
methanol (MeOH)/ddH20 (50:50 v/v) containing a mixture of the internal standards [1 mg/ml of CDCA-d4, CA-d4, DCA-d4, and LCA-d4
(C/D/N Isotopes, Pointe-Claire, Canada)]. The resultant mixture was
added to the preconditioned solid-phase extraction (SPE) (Strata-X;
Phenomenex, Torrance, CA) column (2 ml MeOH, followed by 2 ml
ddH2O). The column was then eluted with 2 ml ddH2O for clearing
unwanted debris. Outflow collection was initiated upon elution with
4 ml MeOH. The eluent was dried under nitrogen gas, reconstituted
with 100 ml MeOH/ddH 2 O mixture, vortexed for 1 minute, and
centrifuged at 12,000g for 10 minutes at room temperature prior to
injection. For plasma sample preparation, 100 ml of sample was added

to 20 ml of the internal standard mixture and precipitated with 1 ml
ice-cold acetonitrile (ACN) containing 5% 1 N ammonium hydroxide
(NH4OH). The mixture was vortexed for 1 minute, centrifuged at
12,000g for 10 minutes at 4°C, and 1 ml supernatant was pipetted and
dried under nitrogen gas. The residue was reconstituted with 100 ml
MeOH/ddH2O mixture, vortexed for 1 minute, and centrifuged at
12,000g for 10 minutes at room temperature prior to injection. For
liver tissue preparation, the liver was homogenized with ddH2O (1:2,
w/v) on ice. The homogenate (100 ml) was then added with 20 ml of
the internal standard mixture and precipitated with 1 ml ice-cold
ACN (in 5% 1 N NH4OH). The mixture was vortexed for 1 minute,
centrifuged at 12,000g for 10 minutes at 4°C, and 1 ml supernatant
was pipetted and dried under nitrogen gas. The residual homogenate mixture was reprecipitated with another 1 ml of ice-cold ACN
(in 5% 1 N NH4OH), vortexed, spun, collected in the same collection
tube, and dried under nitrogen gas. The residue was reconstituted
with 100 ml MeOH/ddH2O mixture, vortexed for 1 minute, and centrifuged at 12,000g for 10 minutes at room temperature prior to
injection.
For preparation of the calibration curves for bile acids in each
biologic matrix, blank sample matrix was first prepared. Blank bile
(diluted 100-fold with ddH2O), plasma, and liver homogenates (1:2,
w/v with saline) were incubated with charcoal (100 mg/ml final
concentration) and the sample was kept shaking overnight at 4°C.
The resulting solution was spun at 9000g for 10 minutes, and the
supernatant was filtered through a 0.45-mm pore size Supor polyethersulfone membrane syringe filter (Pall Life Sciences, Port
Washington, NY). When these blank sample matrices were tested for
the presence of bile acids with LC-MS/MS, none was found (below
limit of quantification). Hence, for standard curves, bile, plasma, and
liver homogenate tissue were first stripped of endogenous bile acids,
then the appropriate standards were added (0.01–10 mg/ml final
concentration for each bile acid species) and processed in the same
manner as described above.
Bile Acid Extraction for Bile Acid Pool Size. The bile acid
extraction procedure was similar to that previously described by Chow
et al. (2014). On the last day of study, mice were fasted for 4 hours
(from 9 AM to 1 PM). The intact gallbladder, liver, and intestine were
removed together under anesthesia. Tissues were minced into pieces
in a beaker containing 50 ml of anhydrous ethanol added with 50 ml of
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hFRGN3
hFRGN4
hFRGN5
hFRGN6
hFRGN7
hFRGN10
hFRGN11
hFRGN12
hFRGN13
hFRGN14
hFRGN15
hFRGN16
hFRGN26
hFRGN27
hFRGN28
hFRGN29
Human liver
Human liver
Human liver
Human liver
Human liver
Human liver
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40-fold), and gallbladder (diluted 5-fold) samples were diluted with
PBS and assayed using a human FGF19 ELISA kit (R&D Systems
Inc., Minneapolis, MN), following the manufacturer’s protocol. We also
tried quantifying Fgf15 levels using enzyme-linked immunosorbent
assay (ELISA). However, these levels were not reported since the
values were considered unreliable (personal communication with
Dr. S. A. Kliewer).
Proteomics. Protein expression (Karlgren et al., 2012) was determined by peptide-based LC-MS/MS measurements (Vildhede et al.,
2014). Quantification of proteins in hFRGN (n 5 9), FRGN (n 5 8), and
human liver (n 5 3) tissues (see Table 1 for donor information) was
accomplished by mass spectrometry–based targeted proteomics using
validated LC2MS/MS methods, as previously described (Groer et al.,
2013).
Tissue was homogenized by a Cellcrusher tissue pulverizer (Schull,
Cork, Ireland). The peptide sequence and multiple reaction monitoring (MRM) transition for each peptide and isotopically labeled peptide
as internal standard for quantification are listed in Table 3. An
isotope-labeled peptide was used as the internal standard for each
peptide (Table 3). Protein was determined by the protein bicinchoninic
acid kit from Pierce Biotechnology (Rockford, IL). An aliquot of 200 mg
membrane protein was digested with Mass Spec Grade Trypsin/Lys-C
Mix (Promega, Madison, WI) (Qiu et al., 2013). Membrane fractions
were extracted using ProteoExtract Native Membrane Extraction
Kit (Calbiochem, San Diego, CA) according to the manufacturer’s
protocol, and 20 ml of the reconstituted, digested sample was injected
into the Shimadzu LC system (LC-30A) (Shimadzu Corp., Kyoto, Japan)
coupled with the ABSciex 6500 QTrap equipped with TurboSpray
ion source operating at positive-ion mode (Foster City, CA). All
chromatographic separations were performed by gradient elution
with a Waters Acquity UPLC Peptide BEH C18 130A 1.7-mm 2.1
150-mm column (Waters Corp, Milford, MA), maintained at 60°C at a
flow rate of 300 ml/min. The gradient program started as 10% mobile
phase A (0.1% formic acid in water), increased to 30% B (0.1% formic
acid in ACN) over 25 minutes, followed by a sharp increase to 90% B
in the next 0.5 minutes, then maintained at 90% B for 2 minutes. The
gradient was then decreased to 10% B in 0.2 minutes, and held for

TABLE 2
Bile acid standards and parameters for LC-MS/MS
Name

Symbol

m/z

Internal Standard

Cholic acid
a-Muricholic acid
b-Muricholic acid
v-Muricholic acid
Chenodeoxycholic acid
Deoxycholic acid
Muricholic acid
Ursodeoxycholic acid
Lithocholic acid
Glycocholic acid
Glycoursodeoxycholic acid
Glycodeoxycholic acid
Glycochenodeoxycholic acid
Glycolithocholic acid
Taurocholic acid
Tauro-a-muricholic acid
Tauro-b-muricholic acid
Tauro-v-muricholic acid
Tauroursodeoxycholic acid
Taurochenodeoxycholic acid
Taurodeoxycholic acid
Taurolithocholic acid
Cholic-2,2,-4-4-d4 acid
Deoxycholic-2,2,-4-4-d4 acid
Chenodeoxycholic-2,2,-4-4-d4 acid
Lithocholic-2,2,-4-4-d4 acid

CA
a-MCA
b-MCA
v-MCA
CDCA
DCA
MCA
UDCA
LCA
G-CA
gUDCA
gDCA
gCDCA
gLCA
tCA
ta-MCA
tb-MCA
tv-MCA
tUDCA
tCDCA
tDCA
tLCA
CA-d4
DCA-d4
CDCA-d4
LCA-d4

407.3→407.3
407.3→407.3
407.3→407.3
407.3→407.3
391.3→391.3
391.3→391.3
391.3→391.3
391.3→391.3
375.3→375.3
464.3→73.9
448.3→73.9
448.3→73.9
448.3→73.9
432.3→73.9
514.3→79.9
514.3→79.9
514.3→79.9
514.3→79.9
498.3→79.9
498.3→79.9
498.3→79.9
482.3→79.9
411.3→411.3
395.3→395.3
395.3→395.3
379.3→379.3

CA-d4
CA-d4
CA-d4
CA-d4
CDCA-d4
DCA-d4
CA-d4
CDCA-d4
LCA-d4
CA-d4
CDCA-d4
CDCA-d4
CDCA-d4
LCA-d4
CA-d4
CA-d4
CA-d4
CA-d4
CDCA-d4
CDCA-d4
DCA-d4
LCA-d4

Declustering
Potential

Collision Energy

Cell Exist Potential

V

eV

V

2125
2125
2125
2125
2130
2130
2130
2130
2120
285
280
280
280
280
2120
2120
2120
2120
2110
2110
2110
2130
2125
2130
2130
2120

225
225
225
225
225
225
225
225
223
274
274
274
274
264
2120
2120
2120
2120
2120
2120
2120
2120
225
225
225
223

25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
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the internal standards (a mixture of 0.25 mg/ml of CDCA-d4, CA-d4,
DCA-d4, and LCA-d4). The content was boiled at 80°C (ethanol boiling point) for 1 hour, and ethanol was added during the heating/
incubation to replace evaporated liquid. After cooling, the extracts
were filtered through Whatman filter paper and adjusted to 50 ml
with ethanol in a volumetric flask. Some extracts were centrifuged
at 10,000g for 10 minutes and filtered through an Ultra-free-MC
centrifugal filter device containing a 0.22-mm polyvinylidene fluoride
(PVDF) membrane (Millipore, Billerica, MA) prior to analysis. Bile
acid standards, prepared in different concentrations (0.1–50 mM),
were extracted in a similar manner.
LC-MS/MS for Bile Acid Quantification. Extracted samples
from bile, plasma, liver homogenate, and bile acid pool size were
analyzed by LC-MS/MS using the AB Sciex API 4000 Triple Quad
LC/MS instrument (Applied Biosystems/ThermoFisher Scientific, Sunnyvale, CA) with electrospray ionization source in the negative ion mode.
Samples (10 ml) were injected and separated by a Kinetex 2.6-mm C18
100A 100  4.6-mm column (Phenomenex), with a SecurityGuard
precolumn (Phenomenex) at 600 ml/min flow rate. The mobile phase
consisted of prefiltered 10 mM ammonium acetate (A) and highperformance liquid chromatography grade ACN (B). A gradient
was used over 20 minutes: 0–6 minutes, 35–35% solvent B; 6–14
minutes, 35–58% solvent B; 14–15 minutes, 58–95% solvent B;
15–16.5 minutes, 95–95% solvent B; 16.5–17 minutes, 95–35% solvent
B; 17–20 minutes, 35–35% solvent B. MS parameters are listed in
Table 2, and a gas temperature of 500°C, ion spray voltage of 3500V,
and column ambient temperature were used. Selective ion monitoring
was employed to detect the conjugated and unconjugated bile acids.
Bile acids were quantified on the basis of area of the peak of the
standard, corrected by area of the appropriate deuterated internal
standard, in calibration curves (Table 2).
FGF19 in Plasma, Liver, Bile, and Gallbladder. Minced,
frozen hFRGN liver tissues were homogenized in phosphatebuffered saline (PBS) (10 mM, pH 7.0; 1:1, w/v) over ice. The resultant
homogenate was sonicated with a cell disrupter and then centrifuged
at 5000g for 5 minutes to provide a supernatant for later analysis.
Plasma (diluted 2-fold), liver supernatant (diluted 5-fold), bile (diluted
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TABLE 3
Specific peptide sequence for detection of surrogate proteins and MRM conditions
Protein

Species
Cross-Reactivity

Peptide Sequence

Q1

CYP7A1/Cyp7a1
CYP7A1
Cyp7a1
Oatp1b2
NTCP/Ntcp
BSEP/Bsep
BCRP/Bcrp
P-gp
MRP2/Mrp2
MRP3/Mrp3
MRP4/Mrp4

Human/mouse/rat
Human
Mouse/rat
Mouse/rat
Human/mouse/rat
Human/mouse/rat
Human/mouse/rat
Human/mouse/rat
Human/rat
Human
Human/mouse/rat

LSSASLNIR
AHILNNLDNFK
LFAVQEIK
SVQPELK
GIYDGDLK
STALQLIQR
SSLLDVLAAR
AGAVAEEVLAAIR
LTIIPQDPILFSGSLR
IDGLNVADIGLHDLR
APVLFFDR

Q3

Declustering Potential

m/z

m/z

V

eV

V

480.8
433.4
474.2
400.7
440.8
515.4
522.9
635.3
885.8
541.6
482.8

760.4
523.1
616.2
614.3
710.2
657.5
644.3
971.4
665.5
697.2
697.4

66
44
66
80
80
90
100
95
90
90
66

23
15
23
17
17
25
25
31
37
20
28

32
20
26
26
26
26
26
25
25
18
21

Cell Exist Potential

appeared for pERK and total ERK. The intensity for each of the 44and 42-kDa bands was normalized individually to GAPDH/Gapdh
(37 kDa) and summed for pERK or total ERK. The ratio of pERK/total
ERK was then calculated.
Statistics. Data were expressed as mean 6 S.E.M. for all data. For
comparison between two groups, the two-tailed paired Student’s t test
was used. The value of P , 0.05 was set as the level of significance.

Results
Characteristics of FRGN, mFRGN, and hFRGN Mice
Liver weights of hFRGN mice were significantly greater
than those of FRGN mice, although the liver and brain
weights of mFRGN mice were smaller than those of FRGN
mice (Table 4). The gross appearance of hFRGN livers appeared
necrotic and consisted of multiple smaller lobes with distended gallbladders compared with of FRGN livers (Fig. 1A).
mFRGN livers appeared abnormal and different, but less
frequently so. All three mouse species showed higher than
baseline plasma ALT levels owing to the withdrawal of NTBC
(the supplement that rescues the liver from toxicity owing to
absence of Fah gene) 3 days prior to experimentation. For the
FRGN mouse, NTBC withdrawal resulted in some degree of
liver damage, shown by the slightly elevated ALT levels. For
the mFRGN mice, the ALT level was close to baseline values
(∼20 IU/ml), suggesting that the foreign mouse hepatocytes
were able to replace damaged naïve mouse hepatocytes and
restore liver function and lessen toxicity. For the hFRGN
mice, the ALT level was the highest, relative to those in
FRGN and mFRGN mice. The reason may be the presence of
excessive bile acids (discussed later) found in the hFRGN
system. Moreover, hFRGN mice contained much higher levels
of liver cholesterol and conjugated bilirubin than those for
FRGN mice (Table 4). Hepatic triglyceride levels in mFRGN
livers (7.36 6 1.57 mg/g) were higher than those of FRGN and
hFRGN livers, although levels in hFRGN livers (3.3 6
1.06 mg/g) were not significantly different from that in FRGN
livers (1.81 6 0.62 mg/g; Table 4). These observations were
consistent with histopathological images with lipid Oil Red O
staining (Fig. 1B).
Bile Acid Composition in Bile, Plasma, and Liver and Bile
Acid Pool Sizes in FRGN, mFRGN, and hFRGN Mice
The composition of bile acids among FRGN, mFRGN, and
hFRGN mice was compared (Fig. 2A; Table 5). In FRGN and
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2 minutes. The mass spectrometer ion spray voltage was 5000V,
temperature was 450°C, curtain gas was at 40 psi, and ion source gas
1 and ion source gas 2 were at 85 and 60 psi, respectively. Detection
was accomplished by mass spectrometry–based targeted proteomics
using validated LC2MS/MS methods, as previously described (Groer
et al., 2013). Analyses were performed in scheduled multiple reactions
monitoring (SMRM) mode. Peak integration and quantification were
performed using the Analyst 1.6.2 software (MDS Sciex, Concord, ON).
The final protein expression (fmol per mg membrane protein) was
calculated upon normalization of the isolated membrane fraction as
described by Li et al. (2008), and the accuracy (error) and precision (CV)
were ,20%. Each sample was analyzed in duplicate (technical repeats).
Quantitative Real-Time Polymerase Chain Reaction. Total
mRNA in tissue was isolated with the standard TRIzol extraction
procedure and quantified as previously described (Chow et al., 2009,
2014). Specific mouse and human primers were designed in PrimerBLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) with exonexon junction span and specificity check for appropriate species (Chow
et al., 2016). Primers were checked against mouse liver and human
hepatocellular carcinoma cell (HepG2) or human liver tissue mRNA and
water for specificity, and the sequences are summarized in Supplemental
Table 1. mRNA was synthesized into cDNA by a High Capacity cDNA
synthesis kit (Applied Biosystems by Life Technologies, Burlington, ON);
cDNA was quantified by the Applied Biosystems 7500 series system
using SYBR Green or TaqMan for detection. For human liver mRNA
analysis, genes were normalized to human glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (detects human). For mouse liver mRNA
analysis, genes for mouse hepatocytes and nonparenchymal cells were
normalized to mouse b-actin (detects mouse), and genes for cholangiocytes were normalized to mouse CK19 (detects mouse), a marker for
cholangiocytes. Target gene data in mouse tissue was normalized to
cyclophilin for brain and kidney, and to villin for the small intestine.
Western Blotting. Protein isolation was performed as previously
described (Chow et al., 2009). Liver homogenate protein samples
(25 mg) were loaded and separated by 12% SDS-polyacrylamide gels,
transferred onto nitrocellulose membranes (Amersham Biosciences,
Piscataway, NJ), then blocked with 5% (w/v) skim milk in Trisbuffered saline and 0.1% Tween 20 (TBS-T; SigmaAldrich Canada) for
1 hour at room temperature, followed by washes with 0.1% TBS-T.
Primary antibody solutions of total ERK (1:5000 dilution) (cat. no.
9102; Cell Signaling Technologies, Danvers, MA) and pERK (1:1000
dilution) (cat. no. 9101; Cell Signaling Technologies) or GAPDH/
Gapdh (1:10000 dilution) (cat. no. ab8245; Abcam, Cambridge, MA)
were prepared in 5% skim milk in 0.1% TBS-T and incubated
overnight at 4°C. On the next day, the membrane was washed with
0.1% TBS-T and then incubated with secondary antibody (1:2000 antirabbit or 1:10000 anti-mouse) in 2% skim milk in 0.1% TBS-T for
2 hours at room temperature, and then washed with 0.1% TBS-T.
Bands were visualized with chemiluminescence reagents (Amersham
Biosciences) and quantified by scanning densitometry. Two bands
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TABLE 4
Physiologic parameters of FRGN, mFRGN, and hFRGN mice (n = 4–9)
FRGN

Body weight (g)
Liver (% body weight)
Brain (% body weight)
Kidney (% body weight)
Plasma ALT (IU/ml)
Plasma cholesterol (mg/dl)
Liver cholesterol (mg/g)
Liver triglyceride (mg/g)
Total biliary bilirubin in bile (mg/dl)
Conjugated bilirubin in bile (mg/dl)

32.1
7.61
1.55
2.08
113
151
2.17
1.81
5.0
1.0

6
6
6
6
6
6
6
6
6
6

3.6
0.27
0.07
0.18
15.5
11.8
0.22
0.62
0.8
0.2

mFRGN

33.0
4.95
1.27
1.82
52.2
161
2.63
7.36

6 7.6
6 0.14†
6 0.06†
6 0.14
6 17.0†
6 11.0
6 0.20
6 1.57†
NM
NM

hFRGN

30.6
10.6
1.56
2.24
215
152
3.14
3.31
11.6
4.9

6
6
6
6
6
6
6
6
6
6

4.0
0.31*
0.11
0.16
30.1*
15.6
0.21*
1.05
4.7
1.8*

NM, not measured.
†
Denotes P , 0.05 compared between mFRGN and FRGN mice using two-tailed Student’s t test.
*Denotes P , 0.05 compared between hFRGN and FRGN mice using two-tailed Student’s t test.

been contributed by many external factors. For the comparison in humans, it must be kept in mind that the human
hepatocytes repopulated in these hFRGN livers were from
either male or female donors, and gender difference in bile acid
metabolism can occur (Fisher and Yousef, 1973); humanization of these livers originating from both male and female
donors were indeed highly variable (Chow et al., 2016). In
addition, gut microbiota are different between mice and
humans, and this may contribute further to differences in
secondary bile acid production (Wahlstrom et al., 2016).
Bile. In hFRGN bile, CA, CDCA, and DCA and their
taurine- and glycine-conjugates, major forms found in
humans, were observed to be significantly higher compared
with those in FRGN bile (Table 5); DCA, gDCA, tDCA, tUDCA,
gUDCA, tLCA, gLCA, a-MCA, and ta-MCA were also considerably higher in hFRGN bile. A detailed comparison of the bile

Fig. 1. Appearance of the FRGN, mFRGN, and hFRGN livers. (A) Gross appearance. Note the abnormal gross appearance, the distended gallbladder,
small lobes, and the necrotic tissue in hFRGN livers. (B) Oil Red O staining at 100 (scaling from 0–250 mm with interval of 50 mm) and 400
magnifications (scaling from 0–50 mm with interval of 10 mm) of FRGN, mFRGN, and hFRGN livers (one representative preparation each). Normal
morphology was observed in FRGN livers, whereas mFRGN livers showed higher lipid deposits than FRGN livers, whereas lipid deposits in hFRGN
livers were only slightly higher. Hepatocytes appeared tightly packed in hFRGN livers.
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mFRGN mice, muricholic acids (a-MCA, b-MCA, and v-MCA)
and their tauro-conjugates, as well as tCA were the major
murine bile acids present in all biologic matrices (Fig. 2A;
Table 5). Overall, implantation of foreign mouse hepatocytes
into FRGN recipients did not greatly alter the bile acid
composition in all biologic matrices (Fig. 2A), although bile
acid concentrations in mFRGN mice were about 1.5- to 3.3-fold
higher than those in FRGN mice (Table 5). For hFRGN mice,
dramatic changes in bile acid composition and dramatically
higher (by several to a few thousand-fold) bile acid levels over
those of FRGN mice were observed in bile, plasma, and liver
(Fig. 2A, Table 5). There were considerably greater glycineconjugates, as expected of human bile acids, although taurine
conjugates were also observed. Muricholic acid and variants of
murine designation persisted in hFRGN plasma, bile, and
liver. These differences in bile acid composition may have
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contents for hFRGN (including FRGN and mFRGN bile) and
human bile was further conducted (Table 6). Even though
levels of the glycine-conjugates of CA, DCA, CDCA, and UDCA
were present in hFRGN bile, suggesting human metabolic
activities, these concentrations were lower relative to those in
human bile (Table 6). Moreover, higher proportions of taurineconjugates as well as muricholic acids (10% total), rodentspecific bile acids formed from Cyp2c70 (Takahashi et al.,
2016), were observed in hFRGN bile, although these are
normally absent in human bile. Species differences in the bile
acid conjugation pathways between human and rodents raised
serious questions about the contribution of murine hepatic
activities in these highly humanized livers, inasmuch as bile
acids are mostly glycinated in human livers but are taurineconjugated in rodent livers (Sayin et al., 2013). The higher
taurine- to glycine-conjugates in hFRGN mice suggests the

presence of remnant mouse hepatocyte activities. In addition,
b-MCA and CA, which are normally conjugated with taurine
in rodents (Sayin et al., 2013), were present abundantly as
58% of biliary bile acids in hFRGN mice, contrasting with the
6.5% CA and 0% MCA observed for human bile (Table 6).
These facts again suggest the persistence of murine hepatic
activities.
Plasma. In plasma, higher levels of human bile acids were
observed in hFRGN mice than in FRGN mice, and MCA and
tMCAs (murine bile acids) in hFRGN plasma were also higher
than those in FRGN plasma (Table 5). DCA, the highly toxic
bile acid, and its conjugated forms, tDCA and gDCA, for
hFRGN were . 220-fold those of FRGN (Table 5).
Liver. In liver, primary and secondary bile acids, such as
MCAs and CDCA were significantly lower in hFRGN mice
compared with those in FRGN mice, but DCA and taurine- and
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Fig. 2. Bile acid composition in (A) bile, plasma, and liver and (B) bile acid pool size (n = 4–8). Note that for hFRGN mice, there were much higher
proportions of CDCA, CA, and DCA and their taurine-conjugates (.85% composition), which are strong FXR ligands, whereas for FRGN and mFRGN
mice, these were 17–44%. By contrast, murine bile acids, muricholic acid (MCA), a-MCA, b-MCA, and v-MCA and their taurine-conjugates, were 53–81%
in FRGN and mFRGN mice and were 13–15% for hFRGN mice. The bile acid pool size was 4.2-fold higher for hFRGN than for FRGN mice. Data are
mean 6 S.E.M.; #P , .05, between FRGN and hFRGN mice, using a two-tailed Student’s t test.

55,567 6 17,757*
9.5
18.3
1.5
1.7
0.4
0.21
14
21.3
14.9
1,816
‘
53
‘
‘
99
‘
0.63
22.9
‘
NA
100
‘

2,003
0.09 6 0.05
0.13 6 0.04
1.22 6 0.91
1.93 6 0.89
0.64 6 0.39
0.58 6 0.22
0.01 6 0
0.2 6 0.1
1.33 6 0.49
,0.01
0.04 6 0.02
0.07 6 0.03
,0.01
0.07 6 0.01
0.09 6 0.03
,0.01
0.06 6 0.04
0.03 6 0.01
,0.01
0.05 6 0.03
,0.01
,0.01

,0.01

4.2 6 1.6

6.6 6 3.1
2.4 6 1.5

FRGN

0.56 6 0.34
0.55 6 0.21
1.83 6 1.21
5.26 6 1.98
0.98 6 0.75
1.31 6 0.47
0.01 6 0.01
0.7 6 0.6
1.47 6 0.50
,0.01
0.09 6 0.06
0.20 6 0.07
,0.01
0.12 6 0.03
0.06 6 0.02
,0.01
0.09 6 0.03
0.07 6 0.02
,0.01
,0.01
,0.01
,0.01

,0.01

8.9 6 3.1

13.3 6 4.7
4.4 6 2.5

mFRGN

1.81 6 0.97
7.13 6 2.93*
3.11 6 0.60
11.8 6 2.67*
2.43 6 0.65
2.61 6 0.48*
0.10 6 0.02*
16.2 6 12.3*
61.4 6 16.9*
24.4 6 10.9*
0.37 6 0.04*
2.61 6 0.98*
0.43 6 0.15*
14.8 6 2.41*
66.8 6 14.7*
103 6 29.6*
0.13 6 0.02
0.38 6 0.11*
,0.01
0.02 6 0.01
0.14 6 0.07
0.31 6 0.11*

129 6 36.6*

153 6 29.1*

321 6 40.1*
39.4 6 14.8*

hFRGN

4.61 6 0.97
0.91 6 0.30
54.6 6 21.9
8.14 6 4.54
7.51 6 2.88
4.03 6 1.67
0.63 6 0.13
3.22 6 0.68
28.1 6 7.5
,0.01
3.06 6 0.46
1.77 6 0.41
,0.01
0.14 6 0.02
1.46 6 0.21
,0.01
2.12 6 0.58
0.88 6 0.20
,0.01
,0.01
0.18 6 0.06
,0.01

1.08 6 0.32
0.32 6 0.18
31.7 6 11.8
0.75 6 0.38
5.84 6 2.3
1.71 6 0.99
0.49 6 0.17
2.89 6 1.05
25.1 6 8.4
0.08 6 0.05
1.35 6 0.36
0.80 6 0.23
,0.01
0.16 6 0.07
2.23 6 1.16
0.06 6 0.03
1.33 6 0.28
0.38 6 0.18
,0.01
,0.01
0.08 6 0.01
0.02 6 0.02
20.1
55
2.5
6.1
3.8
4.5
10
76
46
‘
9.2
38
‘
221
725
‘
2.2
12.7
NA
0.4
‘
‘

a

0.35 6 0.12*
9.17 6 2.12*
1.23 6 0.24*
31.2 6 3.52*
0.35 6 0.08*
3.23 6 0.92
0.03 6 0.01*
4.58 6 3.36
165 6 36.4*
17.1 6 7.0*
,0.01*
8.47 6 1.84*
0.87 6 0.27*
1.54 6 0.67*
161 6 18.8*
21.2 6 4.9*
,0.01*
1.74 6 0.25*
0.08 6 0.08
,0.01
1.74 6 0.43*
0.07 6 0.02

39.3 6 9.7*

,0.01

0.16 6 0.09

‘

382 6 39.8*

31.3 6 10.2 45.5 6 12.6

a

37

hFRGN

429 6 42.2*
8.1 6 4.0*

mFRGN

76.4 6 24.2 121 6 38.0
44.8 6 15.2 75.9 6 25.6

FRGN

49
17

hFRGN to
FRGN Ratio

Liver (nmol/g)

and * denote P , 0.05 compared between mFRGN and FRGN mice and hFRGN and FRGN mice, respectively, using two-tailed Student’s t test or Mann-Whitney test; NA, not applicable.
‘

24.9 6 11.3
88.0 6 17.3*
5580 6 1,904
9536 6 3,077*
143 6 41.8
95.6 6 19.2
35,606 6 11,721 16,354 6 3,530
68.7 6 21.9
24.5 6 5.3
11,766 6 5,849
1021 6 308*
,0.01
1.4 6 0.68
51 6 16
2502 6 680*
22,085 6 11,681 109,010 6 24,806*
52 6 32
50,400 6 15,742*
,0.01
1.96 6 0.27*
763 6 123†
8,503 6 3,440*
,0.01
671 6 287*
,0.01
38.5 6 12.2*
581 6 151
36,171 6 12,732*
,0.01
4200 6 1925*
1.1 6 0.3
0.5 6 0.3
630 6 237†
2654 6 1396*
,0.01
277 6 157*
,0.01
,0.01
14.4 6 3.7†
269 6 131*
,0.01
17.9 6 8.1*

52 6 33

8

77,027 6 31,201 183,520 6 32,047*

hFRGN to
FRGN Ratio

10.5
10.9

hFRGN

77,369 6 31,272 241,840 6 47,453*
288 6 88
2752 6 698*

mFRGN

Plasma (mM)
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†

Total BA
23,137 6 4290
Primary +
252 6 98
secondary BA
Tauro22,857 6 4262
conjugated BA
Glyco28 6 10
conjugated BA
a-MCA
9.3 6 4.8
ta-MCA
522 6 150
b-MCA
63.3 6 22.9
tb-MCA
9507 6 2720
v-MCA
61.6 6 27.6
tv-MCA
4863 6 1,265
MCA
0.1 6 0.15
CA
117 6 47
tCA
7318 6 1484
gCA
28 6 10
CDCA
,0.01
tCDCA
160 6 33
gCDCA
,0.01
DCA
,0.01
tDCA
367 6 262
gDCA
,0.01
UDCA
0.8 6 0.2
tUDCA
116 6 28
gUDCA
,0.01
LCA
,0.01
tLCA
2.7 6 1.2
gLCA
,0.01

FRGN

Bile (mM)

TABLE 5
Bile acid concentrations in bile, plasma, and liver (data of Fig. 2A) of FRGN, mFRGN, and hFRGN livers (n = 4–8, mean 6 S.E.M.)

0.32
29
0.04
42
0.06
1.9
0.06
1.6
6.6
207
,0.01
10
‘
9.8
72
348
,0.01
4.6
NA
NA
22
3.5

240

12

5.6
0.2

hFRGN
to FRGN
Ratio
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TABLE 6
Comparison of biliary bile acid composition to that in healthy adults according to Rossi et al. (1987) in
human bile (t and g denote taurine- and glycine-conjugated bile acids, respectively)
(% Assayed Bile Species)
FRGN

mFRGN

hFRGN

0.52
31.2
0.11
0
1.50
0
0
0.69
0
0
0.64
0
0.04
2.29
0.28
40.7
0.27
21.7
0.01
Not assayed
0
Not assayed
Not assayed

0.09
24.3
0.05
0
0.98
0
0
1.40
0
0
0.88
0
0.04
7.61
0.23
51.4
0.11
12.8
0.03
Not assayed
0
Not assayed
Not assayed

1.41
47.4
19.0
0.02
14.9
1.59
0
3.44
0.25
0
0.89
0.09
0.04
3.74
0.05
6.76
0.01
0.40
0.12
Not assayed
0.01
Not assayed
Not assayed

glycine-conjugated bile acids were 9.8x, 72x and 348x higher,
respectively (Table 5). The murine bile acids were higher in
hFRGN livers: ta-MCA, tb-MCA, and tv-MCA concentrations in
hFRGN livers were 29-, 42-, and 1.9-fold those in FRGN liver,
respectively (Table 5).
Bile Acid Pool Sizes. The extremely high levels of bile
acids in bile, plasma, and liver observed in hFRGN mice
prompted us to compare the bile acid pool sizes between
hFRGN and FRGN mice. The bile acid pool size for hFRGN
mice (n 5 4) was found to be 4.2-fold that of FRGN mice (n 5 4)
(Fig. 2B). Human conjugated bile acids such as tCDCA, tDCA,
tUDCA, tLCA, gCA, gCDCA, gDCA, gDCA were significantly higher in hFRGN mice, and the MCA content in hFRGN
mice was proportionately lower, although not absent. Glycoconjugates, tauro-conjugates, and DCA were almost 1,000-fold
(gCDCA, 2,220-fold; gCA, 943-fold; gDCA, 1,140-fold), 4.2-fold
(tDCA, 26-fold; tCA, 6.3-fold), and 8.7-fold higher in hFRGN
mice, respectively (Fig. 2B). The presence of the much higher
proportions of DCA, tDCA and gDCA, highly toxic bile acids,
would render greater toxicity to the liver (Delzenne et al., 1992).
Comparison of Basal Human mRNA Expression between
hFRGN Livers and Normal Human Liver Tissues
hFRGN livers and human liver tissues were examined to
compare basal human mRNA and other underlying changes.
For examination of whether any of the bile acid synthetic
pathways were altered, mouse and human enzymes in hFRGN
livers and human liver tissues were measured (Fig. 3). CYP7A1,
or CYP 7a-hydroxylase, the rate-limiting enzyme for the classic
(major) pathway in bile acid synthesis; oxysterol 7a-hydroxylase
or CYP7B1, the rate limiting enzyme in the alternative (acidic)
pathway for CDCA production; CYP27A1, the alternative
enzyme for CDCA production in both the classic and alternative pathways; and murine/human bile acid CoA/amino
acid N-acyltransferase (BAAT; conjugative enzyme) (Chiang,
2009) were evaluated. As shown in Fig. 3A, there was no

Humans

6.5
34.1
2.1
13.6
5.1
28.9
0.9
1.5
0
0
0
0
0
0
0.1
0.2
0.6
0.2
6.0

difference in human hepatic CYP27A1, CYP7B1, and BAAT
mRNA expression between hFRGN livers and human livers,
except for human CYP7A1 mRNA expression, which was 120-fold
higher in hFRGN over human liver tissue (Fig. 3A). By contrast,
mouse liver Cyp7b1, Cyp27a1, and Baat mRNA expression (Fig.
3B) in hFRGN livers were much lower than those for FRGN and
mFRGN mice.
The mRNA expression of human CAR, human hepatocyte
nuclear factor 4 alpha (HNF-4a), peroxisome proliferatoractivated receptor (PPARg), albumin, b-Klotho, CYP2E1,
glutathione S-transferase (GSTA4-4), UGT1A1, organic
anion–transporting polypeptides (OATP1B1 and OATP1B3),
bile salt export pump (BSEP), ABCG5, ABCG8, OSTa2OSTb,
multidrug resistance protein 1 (MDR1), and multidrug
resistance–associated protein 2 (MRP2) were also higher (1.5to 2.5-fold) in hFRGN livers over those in human liver tissue
(Fig. 3A), whereas those for FXR and SHP were lower in
hFRGN livers. One plausible reason for the lower FXR expression is the presence of extremely high levels of taurine-conjugated
MCAs (Table 5), FXR antagonists (Sayin et al., 2013); inhibition
of FXR would lead to the reduction in SHP expression (Fig. 3A).
Those for CYP1A1, CYP2C19, breast cancer resistance protein
(BCRP), OSTa, and OSTb mRNA levels in hFRGN livers were
2.5-fold higher, with a notable 100-fold higher CYP7A1 mRNA
level in hFRGN livers compared with those in human liver tissue
(Fig. 3A). Despite the high bile acid contents in hFRGN livers
(Table 5), the mRNA expression of MRP3, a bile acid–associated
FXR target, was unexpectedly lower (Fig. 3A).

Miscommunication among Human Hepatocytes and Murine
Nonparenchymal Cells (Mouse Kupffer Cells, Stellate Cells,
and Cholangiocytes) in hFRGN versus FRGN and mFRGN
Livers
The communication between human hepatocytes and
mouse nonparenchymal cells in hFRGN livers was evaluated
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Fig. 3. Hepatic mRNA expression of (A) human genes in hFRGN livers (n = 11) and those in human liver tissues (n = 6) and (B) murine genes present in
FRGN, mFRGN, and hFRGN livers (n = 4–8). Hepatic human mRNA expression in hFRGN livers was generally higher than in human liver tissue,
whereas FXR and SHP mRNA expression was significantly lower (A). Mouse Tgf-b1, the antiproliferative gene in nonparenchymal cells, was unchanged,
whereas mRNA expression of other murine bile acid metabolic enzymes in mouse hepatocytes and murine proliferative markers and apical sodiumdependent bile acid transporter (Asbt) in cholangiocytes were lower in hFRGN livers (B). Data are mean 6 S.E.M.; †P , .05, between human livers and
hFRGN livers; *P , .05, between FRGN and mFRGN livers; #P , .05, between FRGN and hFRGN livers, using a two-tailed Student’s t test.

to assess the proliferation status. Since the transforming
growth factor beta receptor 2 (TGFBR2) in human hepatocytes, and Tgf-b1 that is produced by a multitude of mouse
nonparenchymal cells, including Kupffer cells, sinusoidal
endothelial cells, dendritic cells and stellate cells (De Bleser
et al., 1997; Schon and Weiskirchen, 2014; Weiskirchen and
Tacke, 2014) are both antimitogenic, these termination signals
were evaluated. TGFBR2 mRNA expression in hFRGN livers

was significantly lower, only 10% that in normal human
liver tissue (Fig. 3A), suggesting continuous hepatocyte
proliferation in hFRGN livers. In addition, mouse Tgf-b1
mRNA level in hFRGN was not elevated compared with
that in FRGN livers (Fig. 3B), suggesting that mouse
stellate/Kupffer cells failed to respond to the high number
of human hepatocytes present in hFRGN livers (Yoshizato
et al., 2012). These results suggest a lack of communication
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in hFRGN livers is a reduction of the cholehepatic shunt,
leading to higher bile acid concentration in bile and the
possibility of generating cystic fibrosis or primary sclerosing
cholangitis characteristics (Glaser and Alpini, 2009; Maroni
et al., 2015).
Proteomics of Human/Murine Liver Protein Abundances in
hFRGN Livers
To investigate the potential role of bile acid dysregulation in
the hFRGN liver, we performed proteomic analysis, the more
quantitative tool to differentiate between human and mouse
proteins in hFRGN livers, to evaluate the absolute transporter
and enzyme changes (Fig. 4). As with the mRNA data (Fig.
3A), the protein expression of human CYP7A1, determined by
LC-MS/MS, was higher (.3-fold) in hFRGN livers than that in
human liver tissue (Fig. 4A). The protein expression of mouse
Cyp7a1, the rate-limiting enzyme in cholesterol metabolism,
in hFRGN livers was only slightly lower compared with that in
FRGN livers, suggesting that the contribution of murine
enzyme for bile acid synthesis in hFRGN liver would not be
negligible despite Cyp27a1 and Cyp7b1 mRNA expression

Fig. 4. Proteomics of liver proteins. (A) With the human-specific peptide, liver CYP7A1 protein level was found to be .3-fold higher in hFRGN livers (n =
9) than in human liver tissues (n = 3); with mouse-specific peptides, murine Cyp7a1 level was found to be comparable to that of FRGN livers, and murine
Oatp1b2 protein persisted in hFRGN liver. (B) Cross-reactive (mouse + human) peptides were also used to detect liver proteins in hFRGN and FRGN
livers (n = 6–8). Data are mean 6 S.E.M.; ND denotes not detected/below detection limit; †P , 0.05, between hFRGN and human livers; #P , .05, between
FRGN and hFRGN livers, using a two-tailed Student’s t test.
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between mouse stellate cells and human hepatocytes that
can lead to continuous proliferation.
To examine further whether proliferation of hepatocytes
had influenced cholangiocyte growth and intrahepatic bile
acid mass, chemokine (C-X-C motif) ligand 16 (Cxcl16)
(Omenetti et al., 2009) and other vascular endothelial growth
factors (Vegf-a and Vegf-c) (Glaser et al., 2014; Meng et al.,
2014), key cell-growth proliferators in cholangiocytes, were
measured (Fig. 3B). The results showed that these markers were
significantly decreased, suggesting that murine cholangiocyte
proliferation was inhibited. In addition, expression of the
transmembrane-bound G protein-coupled receptor (Tgr5)
that is activated by bile acids (especially tLCA and tDCA)
(Keitel and Haussinger, 2013; Duboc et al., 2014; Reich
et al., 2016) and localized in cholangiocytes and modulates cholangiocyte proliferation and bile flow, was lower
(Fig. 3B). The apical sodium-dependent bile acid transporter (Asbt), regulated by cAMP and Tgr5 (Xia et al., 2006;
Keitel and Haussinger, 2013) in cholangiocytes, was also
lower in hFRGN livers (Fig. 3B). The results suggest a decrease
in cholangiocyte proliferation and bile acid reuptake (Lazaridis
et al., 1997). The expected consequence of downregulated Tgr5
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Miscommunication between Human Hepatocytes and
Murine Intestine
The potential Fgf15 and FGF19 signaling pathway on
hepatic human CYP7A1 regulation in hFRGN mice was
evaluated to assess the communication between murine
intestine and human hepatocytes. Levels of FGF19 in liver,
bile, gallbladder, and plasma, when assayed with ELISA,
were found absent (data not shown). Levels of Fgf15 in
plasma, though measured with ELISA, remained uncertain
since the measured values are unreliable (personal communication with Dr. Steven A. Kliewer). Intestinal murine
Fgf15 mRNA expression, therefore, served as a biomarker
of what the circulating Fgf15 levels would have been. In
hFRGN intestine, Fgf15 expression was significantly induced (500-fold), probably by intestinal Fxr activation (Fig.
5A), a line of reasoning that is supported by induction of all
other intestinal Fxr targets, such as Osta, mouse ileal bile
acid binding protein (Ibabp), and Shp, since high levels of bile
acid in hFRGN mice were observed (Fig. 2B). In addition, the
apical sodium-dependent bile acid transporter (Asbt) expression (Fig. 5A) was lower in hFRGN intestine, probably owing
to inhibition by the Fxr-Shp murine/human liver receptor
homolog 1 (Lrh-1) cascade (Chen et al., 2003) or inhibition by
Fgf15 (Sinha et al., 2008). Moreover, analyses of phosphorylated ERK (pERK) and total ERK protein (Fig. 5B), an
indicator of FGFR4 activation in human hepatocytes, showed
that both pERK and the ratio of pERK/total ERK were
similar in FRGN and hFRGN livers, suggesting that the
increase in Fgf15 did not result in higher activation of
FGFR4/b-Klotho signaling pathway in human hepatocytes. As
a result, CYP7A1 protein expression in hFRGN remained
elevated compared with that for human liver tissue (Fig. 4A),
drastically increasing the bile acid pool size in hFRGN mice
(Fig. 2B).
Changes in Basal mRNA Expression in Other Mouse Tissue
Changes in nuclear receptor, transporter, and enzyme
expression in the mouse intestine, kidney, and brain were

also evaluated among FRGN, mFRGN, and hFRGN mice to
assess the potential impact of bile acid dysregulation on
interorgan communication.
Intestinal Genes. The basal mRNA levels of different
intestinal genes were generally similar between FRGN
and mFRGN intestine (Fig. 6). However, levels were much
different between FRGN and hFRGN intestine. For important xenobiotic intestinal genes, higher Car and Pxr levels
as well as Mdr1a, Mrp4, murine glutathione S-transferase
(Gsta4-4), sulfotransferase (Sult1a1), and UDP-glucuronosyltransferases (Ugt1a1) were observed in hFRGN intestine
(Fig. 6). Fluctuations in intestinal Oatp2b1 and Gsta3-3 were
found in mFRGN and hFRGN intestine, and slightly lower
intestinal Mrp3 (all three segments) and Bcrp (ileal segment)
were observed for the hFRGN intestine. The basis for these
differences is currently unknown since both higher LCA (a Pxr
agonist) and human bile acids (strong Fxr agonist) coexisted in
the intestine.
Renal Genes. Only minor differences in renal genes between mFRGN and FRGN mice were observed (Supplemental
Fig. 1), and variations in Lxra, Pxr, Oapt1a1, Oatp1a4, Ost-b,
Oat1, Oat3 and Sult1a1 expression were small. However,
when the basal expression of FRGN and hFRGN kidneys was
compared, greater changes were observed. Renal Pxr and
Car levels were found to be increased, and Lxra levels were
decreased in hFRGN mice. In addition, renal mRNA expression of Oatp1a4, Ost-a, Ost-b, Mrp2, Mrp3, Mrp4, and Gsta4-4
were all elevated in hFRGN mice, though vitamin D receptor
(Vdr), Oapt1a1, Oat1, mouse oligopeptide transporter 2 (PepT2),
and Cyp2e1 levels in hFRGN mice were lower compared with
those of FRGN mice. The data suggest that many of the
observed changes could have been the result of Fxr- and Pxrmediated regulation resulting from the high levels of bile
acids.
Brain Genes. Only minor changes in brain nuclear receptors and transporters were observed between mFRGN and
FRGN mice (Supplemental Fig. 2). Changes in transporter
were small, although expression of Oapt1a4, Oatp2b1, and
Mdr1a levels were increased. Levels of Cyp1a2, Cyp2e1,
Cyp3a11, Gsta3-3, and Ugt1a1 were significantly lower in
hFRGN brain compared with those of FRGN brain.

Discussion
Development of the h-chimeric mouse liver model has been
hailed as a useful in vivo tool for the study of human liver
metabolism. Many studies supported the presence of human
enzyme and transporter expression in humanized mouse
livers (Katoh et al., 2005a, 2005c; Nishimura et al., 2005),
and pharmacokinetic studies in humanized mice showed the
presence of in vivo human metabolites (Okumura et al.,
2007; Grompe and Strom, 2013; Bateman et al., 2014).
However, other studies using chimeric models showed that
the levels of in vivo human metabolites were unpredictable
and different from those in humans (De Serres et al., 2011;
Liu et al., 2011; Sanoh et al., 2012).
In our previous study, we identified two key issues on the
discordance of the humanized model. We unveiled the presence of remnant native mouse hepatocytes and loss of metabolic
zonation in hFRGN livers (Chow et al., 2016). In the present
report, histopathologic, biologic, mRNA, and proteomics (using
LC-MS/MS) data provided additional evidence to suggest
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levels being much lower (Fig. 4B). Remnant protein expression of murine Oatp1b2, the ortholog of human OATP1B1 and
OATP1B3 (Evers and Chu, 2008), was also observed (Fig. 4B).
Owing to a lack of species specificity in protein sequence
[sodium-dependent taurocholate–cotransporting polypeptide
(Ntcp/NTCP), Bcrp/BCRP, Bsep/BSEP, Mrp2/MRP2, Mrp3/
MRP3, Mrp4/MRP4, and P-glycoprotein (P-gp)] of the peptides, a comparison between the amounts of human- and
mouse-specific protein in hFRGN and FRGN livers could not
be made in the proteomic analyses. Rather, the comparison was
conducted using either mouse-specific or cross-reactive peptide
for the target proteins in FRGN and hFRGN livers. In Fig. 4C,
protein contents in Ntcp/NCTP and Bcrp/BCRP were found to
be lower for hFRGN livers than for FRGN livers, whereas levels
for the ATP transporters (Mrp2/MRP2, Mrp3/MRP3, and Mrp4/
MRP4 and P-gp) were all higher. Protein differences of Ntcp/
NTCP, Mrp4/MRP4, and murine/human P-gp in FRGN and
hFRGN livers were consistent with those protein levels previously measured with immunoblotting (Chow et al., 2016),
which may also be reflective of cross-reactive peptides. In
addition, these protein data were consistent with those for
mRNA expression that have been published (Chow et al., 2016).
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Fig. 5. (A) mRNA expression of murine intestinal nuclear receptors, enzymes, and transporters related to bile acid transport/metabolism and (B) the
ratio of pERK/total ERK protein levels (in liver) as an activation indicator of the Fgf15-FGFR4 signaling pathway in FRGN, mFRGN, and hFRGN mice
(n = 4–8). *P , .05, between FRGN and mFRGN intestine of same segment or liver; #P , .05, between FRGN and hFRGN intestine of same segment or
liver; aP , 0.05, between FRGN duodenum and FRGN jejunum or ileum using two-tailed Student’s t test.

instability of the model, including the 4.2-fold bile acid pool
size, the much higher levels of the toxic bile acid, DCA, and
its conjugates (Fig. 2B), the uncontrollable human hepatocyte
proliferation and liver deformity (Figs. 1 and 3), bile acid
dysregulation (Table 5; Fig. 2), toxicity (Table 4), enlarged

gallbladder filling (Fig. 1A), and significant changes in extrahepatic transporters and enzymes (Figs. 5 and 6, Supplemental
Figs. 1 and 2). Although the model is being used increasingly as
a tool for drug discovery and development to relate to human
drug metabolism and toxicity, it is recognized that many of
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Fig. 6. In intestine, mRNA expression of mouse nuclear receptors, transporters, and enzymes in FRGN, mFRGN, and hFRGN mice (n = 4–8). Higher
levels of Car and Pxr in hFRGN intestine were observed. Higher levels of Mdr1a, Mrp4, Gsta4-4, Sult1a1, and Ugt1a1 were present in most intestinal
segments of hFRGN intestine, although higher Gsta4-4 and Sult1a1 expression, though lower Mrp3 and ileal Bcrp, was observed in mFRGN intestine
(mechanism unknown); other changes between FRGN and mFRGN were minor. *P , 0.05 denotes comparison between FRGN and mFRGN intestine of
same segment; #P , 0.05 denotes comparison between FRGN and hFRGN intestine of same segment; aP , 0.05, between FRGN duodenum and FRGN
jejunum or ileum, using two-tailed Student’s t test.

188

Chow et al.

these deficiencies have been previously overlooked and not
properly addressed.
Dysregulated liver regeneration and deformity in hFRGN
livers were evidenced by the miscommunication between
human hepatocytes and murine stellate cells, leading to
substantial hepatocyte proliferation, reduced intracellular
spaces (Chow et al., 2016), and inhibited cholangiocyte
growth. The signaling in hepatocytes and nonparenchymal
cells between TGFBR2/TGF-b plays a critical role in liver
regeneration (Yoshizato et al., 2012). Studies with cultured
hepatocytes have shown that TGF-b1 and TGFBR2 are antimitogenic for hepatocytes. Under normal resting (physiologic)
condition, hepatocytes express TGFBR2, whereas nonparenchymal cells express low levels of TGF-b1. When the liver is injured,
TGFBR2 expression in hepatocytes is reduced to initiate
proliferation. Once an adequate number of hepatocytes is

produced, the stellate cells surround the hepatocytes and
produce TGF-b, which signals to hepatocytes to terminate
proliferation and negatively inhibit TGF-b1 expression
(Yoshizato et al., 2012). Our results showed that hFRGN
livers consisted of remarkably lower TGFBR2 expression,
but an unchanged murine Tgf-b1 expression compared to
that for FRGN livers (Fig. 3). Histopathologic images from
current (Fig. 1A) and previous studies (Chow et al., 2016)
support the evidence of unchecked hepatocyte proliferation
and densely populated liver (Fig. 1A). Invasive hepatocyte
proliferation and inhibited cholangiocyte growth (Fig. 3B)
resulted in reduced bile flow (Chow et al., 2016) and cholehepatic shunting and increased hepatic bile acid accumulation
and toxicity (Tables 4 and 5). The densely populated hFRGN
livers may further lead to ischemia within the acinus, a
condition that leads to inhibition of FXR (Cheng et al., 2013).
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Fig. 7. Schematics depicting the interaction between
(A) the murine intestine and murine liver and bile acids
(denoted as BA), and (B) the murine intestine and
humanized liver. (A) Normally, there are two major
pathways for Cyp7a1 regulation: 1) in liver, by the FxrShp-Lrh-1 or Hnf-4a cascade and 2) in murine intestine by Fgf15, secreted by the ileum and under Fxr
stimulation, to react with Fgfr4 in liver to repress
Cyp7a1. (B) Owing to the over-production of murine bile
acids by the hFRGN liver, the conjugated MCAs that
are strong FXR antagonists, inhibited liver FXR,
whereas strong FXR ligands stimulated intestinal Fxr
targets: murine Shp, Fgf15, Ibabp, and Osta. However,
miscommunication between the murine intestinal
Fgf15 and human FGFR4 and inhibition of the liver
FXR-SHP cascade failed to repress CYP7A1 expression.
Consequently, CYP7A1 expression levels remained
elevated for the synthesis of bile acids, and high BAs
prevailed in this vicious circle. Note that blue lines
represent stimulation, whereas red line represents
inhibition. Solid line denotes activation/increased pathway, whereas dotted lines denote the absence/decrease
of the pathway.
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hepatocytes and mouse nonparenchymal cells in TK-NOG
mouse would also exist. To alleviate elevated bile acids levels,
Naugler et al. (2015) suggest that human bile acid production
can be controlled by administration of exogenous FGF19
in chimeric mice. However, the dose and dosing regimen of
FGF19 administration and the associated effects on drug metabolism and transport are unknown. In addition, the disrupted
signaling of human hepatocyte proliferation in the mouse liver
requires implantation of human Kupffer cells in mouse liver
(Wilson et al., 2014) or exogenous administration of human
TGF-b. Certainly, TGF-b and FGF19 are some of the important signaling mechanisms worth investigation for the optimization of humanized mouse liver models.
The distension of the gallbladder, the unchecked hepatocyte
proliferation and liver deformity, and miscommunication between liver cell types in the humanized liver and between the
mouse intestine and humanized liver, as well as the lack of
negative feedback control of the FXR-SHP cascade on bile acid
homeostasis (Fig. 7B) would bring about liver toxicity and
model instability. These problems will exist not only in the
hFRGN mice, but also in other chimeric (humanized) mice
such as the PXB and TK-NOG chimeric mice. The dysregulation of bile acid production in h-chimeric mice and physiologic
changes that accompany the accumulation of highly toxic bile
acids will further contribute to changes in expression of
transporter and enzyme in extrahepatic tissues (Fig. 6 and
Supplemental Figs. 1 and 2), which would constitute another
important consideration in pharmacokinetics and drug
disposition studies. Activation of other nuclear receptors,
Pxr and Car, owing to elevated bile acids, LCA, and the
metabolite 3-keto-5b-cholanic acid (Goodwin and Kliewer,
2002) may result in changes in transporters and enzymes.
Bile acids, especially the tMCAs and elevated bilirubin levels
in hFRGN livers will further contribute to varying extent of
Fxr and Car induction in extrahepatic tissues (Huang et al.,
2003; Chen et al., 2011). These translate to induction of
targeted transporters and enzymes such as Mrp2, Mrp3,
Mrp4 and Mdr1a, Gst4-4, Sult1a1, and Ugt1a1 (Huang
et al., 2003; Zollner et al., 2006; Zollner and Trauner, 2009;
Wagner et al., 2011) in hFRGN intestine, kidney or brain
(Figs. 6 and Supplemental Figs. 1 and 2) and drug
dispositional changes. To conclude, instability of the hFRGN
liver and extrahepatic tissue with respect to nuclear receptor
activation by the dramatic production of differential human
(CDCA and CA) and murine (tMCAs) bile acids, both FXR
agonists and antagonists, followed by stimulation of the
murine intestine and miscommunication among liver cell
types and between intestine and humanized liver will induce
toxicity and instability issues in this preparation for human
drug metabolism studies.
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The inability of humanized mouse livers to regulate
CYP7A1 expression led to high bile acid levels and toxicity.
Normally, Cyp7a1/CYP7A1 in liver is under Fxr/FXR and
Fgf15/FGF19 control (Fig. 7A). At high bile acid levels, Fxr/
FXR in the intestine activates intestinal Fgf15/FGF19, which
forges an interaction with Fgfr4/FGFR4 to repress Cyp7a1/
CYP7A1 (Inagaki et al., 2005). In liver, the FXR-SHP-LRH-1
or FXR-SHP-HNF-4a cascade negatively controls CYP7A1
(Goodwin and Kliewer, 2002). hFRGN mice displayed higher
levels of CDCA, DCA, and CA and their conjugates (Fig. 3B),
which are strong FXR/Fxr ligands (Makishima et al., 2002),
leading to intestinal Fxr activation and intestinal Fgf15
induction (Fig. 5A). However, hFRGN livers exhibited high
CYP7A1 expression (Fig. 4A), suggesting that the signaling
pathway associated with Fgf15 appeared to be nonfunctional,
as shown by the unchanged ratio of pERK/total ERK (Fig. 5B),
suggestive of human hepatocytes and murine intestine miscommunication. Additionally, SHP levels in hFRGN livers
(Fig. 3A) were lower, suggesting that high bile acid concentration (Table 5) failed to activate hepatic human FXR to
suppress CYP7A1 in hFRGN livers. A plausible explanation
attributes this to the bile acid composition changes in hFRGN
livers: absence of CDCA and high levels of tb-MCA (29-fold)
and ta-MCA (42-fold) (Table 5), which are FXR antagonists
(Sayin et al., 2013). These differential abundances in tMCA
and CDCA appear to be the driving forces for decreased
hepatic FXR activation in hFRGN livers. High bile acid levels
could also induce toxicity by activating nuclear factor-kappa B
(NF-kB), which is associated with higher interleukin-6 and
COX-2 expression toward enhanced growth and apoptosis
resistance in cholangiocarcinoma cells; the release of cytokines can also cause biliary damage (Liu et al., 2014).
High bile acid concentrations in hFRGN bile (Table 5) may
lead to gallbladder filling in hFRGN mice (Fig. 1A), in events
that are related to bile acid-mediated activation of Tgr5,
the transmembrane G-protein-coupled receptor expressed in
cholangiocytes and gallbladder epithelial cells (Li et al., 2011;
Keitel and Haussinger, 2013; Duboc et al., 2014). Activation of
the Tgr5 in gallbladder smooth muscle cells by bile acids,
especially lithocholic and deoxycholic acids and their tauroconjugates, would result in smooth muscle cell relaxation,
gallbladder filling, and gallbladder stasis (Lavoie et al., 2010;
Jones et al., 2015).
Even though high bile acid levels in hFRGN mice were observed, plasma cholesterol level, which is maintained by the
low-density lipoproteins (LDL) and high-density lipoproteins
(HDL), remained unchanged, whereas liver cholesterol was
increased (Table 4). The exact mechanism for these changes
is currently unknown. Ellis et al. (2013) reported that LDL,
VLDL, and HDL fractions were shifted in chimeric mice,
suggesting possible differences of lipid formation and uptake
mechanism. Although murine/human 3-hydroxy-3-methylglutaryl-CoA reductase (HMG CoA reductase; which synthesizes cholesterol) levels (Fig. 3A) in hFRGN livers were similar
to those in human livers, cholesterol synthesis rates between
human and mouse may be different. Certainly, studies are
needed to evaluate the upstream pathways of cholesterol
synthesis in chimeric livers.
The recent TK-NOG chimeric model may be a better option
than hFRGN mice for control of the level of humanization
in the mouse liver (Kim et al., 2014). However, the same
disrupted signaling between the murine intestine and human
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